Skip to Content

Weekly Drug News Round-Up: July 20, 2016

FDA Approves Belviq XR Extended-Release Tablets

Belviq XR is expected to be available commercially in the fall of 2016 Read More...

Belviq is a serotonin 2C receptor agonist indicated for chronic weight management in adults who are obese or overweight based on body mass index (BMI) with at least one weight-related condition such as high blood pressure, type 2 diabetes, or high cholesterol. This week, the FDA approved Eisai Inc. and Arena Pharmaceuticals’ Belviq XR (lorcaserin HCl) CIV extended-release 20 mg tablets taken once-daily. Belviq is the original 10 mg twice-daily formulation. Other more recent approvals for weight loss include Qsymia (phentermine and topiramate), Contrave (bupropion and naltrexone), and Saxenda (liraglutide). Learn more with this slideshow on weight-loss treatments.

Kovanaze Nasal Spray Approved for Dental Anesthesia

Kovanaze delivers a local dental anesthetic but without the scary needle Read More...

Are you fearful of the dentist and the painful shots to numb your mouth? You are not alone. However, your fears may be lessened as the FDA has now approved St. Renatus’ Kovanaze (tetracaine HCl and oxymetazoline HCl) Nasal Spray, the first product for dental local anesthesia to be administered through a nasal spray without using a needle. Kovanaze is intended for use in dentistry as a topical anesthetic, delivered in the nasal cavity to achieve pulpal (tooth nerve) anesthesia for the restorative treatment of teeth. Kovanaze is used for Teeth 4-13 and A-J in adults and children who weigh 40 kg or more.

Nationwide Recall: Diocto Liquid, Docusate Sodium Solution

FDA and CDC recommend that ANY liquid docusate sodium product not be used for any purpose Read More...

PharmaTech LLC of Davie, FL, the manufacturer of the Rugby-branded product, is voluntarily recalling all non-expired lots of Diocto Liquid, a docusate sodium solution due to a risk of contamination with Burkholderia cepacia. FDA has received reports of B. cepacia infections in some patients. Use of docusate sodium liquid contaminated with B. cepacia may result in life-threatening infections in immunocompromised patients and those with chronic lung conditions such as cystic fibrosis. Some of these reports identify liquid docusate sodium products manufactured by companies other than PharmaTech. FDA joins CDC in recommending that ANY liquid docusate sodium product not be used for any purpose.

Is There A Preferred Type 2 Diabetes Drug?

Metformin also carries a low risk of dangerous hypoglycemia (low blood sugar) Read More...

In a new study published July 19 in the Journal of the American Medical Association, researchers found no one type 2 diabetes drug stands out from any others with regard to reducing the risks of heart disease, stroke or premature death. In the study, researchers looked at 301 clinical trials testing nine classes of diabetes drugs, including metformin, and sulfonylureas, plus thiazolidinediones like pioglitazone (Actos) and rosiglitazone (Avandia); and DPP inhibitors, such as sitagliptin (Januvia) and saxagliptin (Onglyza). However, experts agree that metformin (Glumetza, Glucophage), a stronghold in the treatment of type 2 diabetes, should be the first-line agent when possible.

Cancer Experts Endorse Latest HPV Vaccine Guidelines

Experts state that HPV vaccination has the potential to prevent tens of thousands of cancers each year Read More...

Few vaccines in the U.S. are more controversial than the human papilloma virus (HPV) vaccine. However, this week The American Cancer Society endorsed the Centers for Disease Control and Prevention (CDC) HPV vaccination recommendations, which include immunizing all preteens against sexually transmitted HPV. In a new report, the cancer society says 11- and 12-year-old girls as well as boys should be vaccinated to guard against cancers associated with HPV. According to the experts, the HPV vaccine has the potential to prevent the vast majority of cervical, vaginal, vulvar, anal, penile, and oropharyngeal cancers.